Abstract
Background: Primary gastric choriocarcinoma is an extremely rare tumour, with a prevalence of 0.8% among stomach cancers. It is an aggressive disease that progresses and rapidly metastasizes with survival expectancy between 6 and 12 months without treatment. The management is controversial as it does not respond to the usual chemotherapy lines used on gastrointestinal cancer and its treatment is not standardized due to the shortage of cases on record, so it must be individualized.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
